Stock Market Response to Strategic Technical Alliances between Drug and Biotechnology Firms

Published on Sep 1, 2016in Journal of Product Innovation Management3.78
· DOI :10.1111/jpim.12305
Dandan Liu4
Estimated H-index: 4
Xiaoling Pu1
Estimated H-index: 1
Mary E. Schramm2
Estimated H-index: 2
(Quinnipiac University)
Traditionally, firms in the pharmaceutical industry have depended on their internal research and development (R&D) capabilities to maintain a productive new product pipeline. During the past two decades, however, the industry's pipeline productivity has decreased compromising the industry's ability to meet shareholder expectations. As a strategy to invigorate pipeline productivity, and impact financial performance, pharmaceutical firms have increased utilization of strategic technical alliances. Earlier research shows that the degree of financial impact resulting from strategic technical alliances varies in terms of partnership type and differences between client and partner firms. This research studies strategic technical alliances between pharmaceutical and biotechnology firms from 1985 to 2012. Event study methodology is used to determine the relationship between stock market response to alliance announcements, measured as cumulative abnormal returns, and factors representing the absorptive capacity of the pharmaceutical firms in the sample. Then, variables indicating the development stage of the drugs included in the alliances are added to assess the effect of project risk on the market response. The study finds that, in general, the stock market responds in a positive manner to strategic technical alliances in the pharmaceutical industry reflecting the market's immediate response, and expectations of future firm value, resulting from the alliance. The degree of the market's response varies in terms of the client firms’ absorptive capacity with new product introductions being the strongest driver. The market responds similarly to alliances across different drug development stages, however, a stronger response is observed in preclinical and extension stages.
  • References (59)
  • Citations (2)
#1Elkin Olaguer Pérez Sánchez (Grupo México)H-Index: 3
#2Iván Darío Toro Jaramillo (UPB: Pontifical Bolivarian University)H-Index: 2
Last.Blanca Yenny Hernandez Sánchez (Grupo México)H-Index: 1
view all 3 authors...
#1Eric Fang (UIUC: University of Illinois at Urbana–Champaign)H-Index: 19
#2Jongkuk Lee (Ewha Womans University)H-Index: 8
Last.Zhi Yang (Hunan University)H-Index: 3
view all 3 authors...
#1Haibin Yang (CityU: City University of Hong Kong)H-Index: 15
#2Yanfeng Zheng (HKU: University of Hong Kong)H-Index: 7
Last.Xia Zhao (CSUDH: California State University, Dominguez Hills)H-Index: 3
view all 3 authors...
#1Chinho Lin (NCKU: National Cheng Kung University)H-Index: 31
#2Ya Jung Wu (Kao Yuan University)H-Index: 3
Last.Cheng Yu Lee (NTU: National Taiwan University)H-Index: 1
view all 5 authors...
#1Konstantinos Kostopoulos (EADA Business School)H-Index: 10
#2Alexandros Papalexandris (OPA: Athens University of Economics and Business)H-Index: 7
Last.George Ioannou (OPA: Athens University of Economics and Business)H-Index: 26
view all 4 authors...
#1Holger Ernst (WHU - Otto Beisheim School of Management)H-Index: 16
#2Ulrich Lichtenthaler (WHU - Otto Beisheim School of Management)H-Index: 23
Last.Carsten Vogt (WHU - Otto Beisheim School of Management)H-Index: 1
view all 3 authors...
View next paperSelection in Strategic Alliance Activity:: Effects on Firm Performance in the Computing Industry